

Autistic spectrum disorder: No causal relationship with vaccines



Although immunization is known to provide effective life-saving benefits for children, it has sometimes been blamed for an array of diseases that have unknown causes (eg, autistic spectrum disorder [ASD], multiple sclerosis and sudden infant death syndrome). This is not surprising, given that immunizations are common and that humans are primed to attribute causality to events that precede an incident. We all use the 'after it, because of it' logic. This is how we learned not to touch a hot stove as young children. Unfortunately, this logic can be faulty. Causality assessment requires careful consideration of a wide range of factors. Beyond the temporal relationship, the consistency of the finding, the strength of the association, the specificity of the association and the biological plausibility, all need to be evaluated before attributing causality (1,2). This article reviews recent controversies surrounding immunizations and ASD, and concludes that there are no data to support any association between immunization and ASD. It replaces the Canadian Paediatric Society's 2001 position statement on this topic (3).

MEASLES, MUMPS AND RUBELLA IMMUNIZATION

In 1998, a report was published (4) purporting to show that the administration of the measles, mumps and rubella (MMR) vaccine to young children leads to a new form of ASD characterized by the presence of chronic inflammatory colonic disease and a loss of acquired cognitive function, possibly due to an impaired absorption of vitamins or micronutrients and/or an increase in intestinal absorption of intact proteins which then stimulate formation of autoantibodies that damage the brain, causing autism. The causality interpretation in the report rested on claims by parents of the eight children studied, who said that their children's problems occurred within days of the MMR vaccination. Many studies have since been performed to examine this purported relationship.

Large population-based epidemiology studies (5-9) in Finland, Denmark, the United States and England have

shown no association between MMR and autism. The evidence in these studies does not meet the consistency of the finding, the strength of the association or the specificity of the association causality assessment criteria. Both the Institute of Medicine (IOM) review and the Cochrane systematic review failed to show any association between MMR and autism. (10,11).

With respect to the biological plausibility criteria, several laboratories have used polymerase chain reaction (PCR) primer-based assays, and have reported detection of the measles virus or its genome in intestinal biopsies and in peripheral blood mononuclear cells of autistic children (12-14). However, PCR techniques are vulnerable to contamination errors (procedures and controls are critical) and overinterpretation errors if only copy number data are used, and further verification and validation of the amplification products are not performed. Real-time PCR is regarded by many as the gold standard for detection of microorganisms in human disease. A subsequent, carefully detailed laboratory study (15) has refuted previous claims and has provided documented explanations for the earlier reported erroneous results by using a more specific real-time fusion gene assay PCR for measles virus detection. This study also showed that there is no evidence of measles virus persistence in the peripheral blood mononuclear cells of children with ASD. Similarly, the report of elevated levels of antibodies in children with autism (16) has also been negated by more recent work (15).

Thus, the purported association between the MMR vaccine and autism fails to meet the causality assessment criteria. In addition, 10 of the 13 authors of the original paper have now retracted their interpretation of a connection between the MMR vaccine and ASD (17).

THIMEROSAL-CONTAINING VACCINES

Thimerosal, a compound that contains ethyl mercury, has been used as an additive to biological therapies and vaccines because of its effect in preventing bacterial contamination, particularly in opened, multidose vials. In

1997, the United States Food and Drug Administration (FDA) Modernization Act called for a review and assessment of the risk of all mercury-containing foods and drugs. This action stimulated the United States Public Health Service and the American Academy of Pediatrics to issue a joint statement in 1999 (18) calling for the removal of thimerosal from vaccines. This action was undertaken as a precautionary measure; there was no evidence that ethyl mercury was harmful at the doses being administered to infants.

Of note, at that time in Canada, in contrast to the United States, the regularly used infant immunization product (pentavalent DTaPIPvHib vaccine) did not contain thimerosal. Only two infant thimerosal-containing vaccines were used – hepatitis B vaccine and influenza vaccine; the latter was not administered to infants younger than six months of age, the age/size of infant of concern. Hence, any concerns about excessive ethyl mercury exposure in young Canadian infants were without foundation. Since 1999, several studies (19-23) have been conducted to evaluate the safety of thimerosal in vaccines. These studies were reviewed in detail by the IOM (10) in 2001 and 2004 with a focus on autism. The IOM Committee concluded that the evidence favoured rejection of a causal relationship between thimerosal-containing vaccines and autism, as

well as MMR vaccine and autism (10). In the absence of experimental or human evidence that vaccination affects metabolic, developmental, immune, or other physiological or molecular mechanisms that are related causally to development of autism, the IOM concluded that the hypotheses generated to date are theoretical. In a separate critical review (24) of published original data, a link between thimerosal-containing vaccines and ASD was not shown. Epidemiological studies that supported a link demonstrated significant design flaws that invalidated conclusions of these studies (10,24). Additional data from Canada published since 2004 also showed no association between thimerosal-containing vaccines and autism (25).

An important factor to consider is what has happened to autism rates since the removal of thimerosal from vaccines. In studies from Canada (25), Denmark (20) and the United States (26) the rates of autism have continued to increase despite removal of thimerosal from vaccines.

Thus, the evidence is in, and the assessment of purported causality is clear. The MMR vaccine and immunization with thimerosal-containing vaccines are not causally associated with, nor are they a cause of, autism or ASD. There is mounting evidence (27) that ASD has a strong genetic component – a very plausible cause for the disorder.

REFERENCES

- Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: The assessment of individual adverse event reports by an expert advisory committee. *Advisory Committee on Causality Assessment. Bull World Health Organ* 2000;78:178-85.
- Folb PI, Bernatowska E, Chen R, et al. A global perspective on vaccine safety and public health: The Global Advisory Committee on Vaccine Safety. *Am J Public Health* 2004;94:1926-31.
- Canadian Paediatric Society, Infectious Diseases and Immunization Committee [Principal author: J Embree]. Measles-mumps-rubella vaccine and autistic spectrum disorder: A hypothesis only. *Paediatr Child Health* 2001;6:387-9.
- Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet* 1998;351:637-41.
- Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. *Lancet* 1998;351:1327-8.
- Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med* 2002;347:1477-82.
- Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. *JAMA* 2001;285:1183-5.
- Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: A time trend analysis. *BMJ* 2001;322:460-3.
- Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps and rubella vaccination and bowel problems or developmental regression in children with autism: Population study. *BMJ* 2002;324:393-6.
- Institute of Medicine, National Academy of Sciences. *Immunization Safety Review: Vaccines and Autism*. Washington DC: National Academy Press, 2004.
- Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev* 2005;(4):CD004407.
- Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. *Mol Pathol* 2002;55:84-90.
- Martin CM, Uhlmann V, Killalea A, Sheils O, O'Leary JJ. Detection of measles virus in children with ileo-colonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. *Mol Psychiatry* 2002;7 Suppl 2:S47-8.
- Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. *Dig Dis Sci* 2000;45:723-9.
- D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. *Pediatrics* 2006;118:1664-75. (Erratum in 2006;118:2608).
- Singh VK, Jensen RL. Elevated levels of measles antibodies in children with autism. *Pediatr Neurol* 2003;28:292-4.
- Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. *Lancet* 2004;363:750.
- Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: A joint statement of the American Academy of Pediatrics and the Public Health Service. *MMWR Morb Mortal Wkly Rep* 1999;48:563-5.
- Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databases. *Pediatrics* 2003;112:1039-48. (Erratum in 2004;113:184).
- Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. *JAMA* 2003;290:1763-6.
- Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: A retrospective cohort study in the United Kingdom does not support a causal association. *Pediatrics* 2004;114:584-91.
- Heron J, Golding J, ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: A prospective cohort study in the United Kingdom does not support a causal association. *Pediatrics* 2004;114:577-83.

23. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: Negative ecological evidence from Danish population-based data. *Pediatrics* 2003;112:604-6
24. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. *Pediatrics* 2004;114:793-804. (Erratum in 2005;115:200).
25. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. *Pediatrics* 2006;118:e139-50.
26. California Department of Developmental Services. Autism <http://www.dds.ca.gov/Autism/Autism_main.cfm> (Version current at April 17, 2007).
27. The Autism Genome Project Consortium; Szatmari P, Paterson AD, Zwaigenbaum L, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat Genet* 2007;39:319-28.

INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE

Members: Drs Robert Bortolussi, IWK Health Centre, Halifax, Nova Scotia (chair); Dorothy L Moore, The Montreal Children's Hospital, Montreal, Quebec; Joan Louise Robinson, Edmonton, Alberta; Élisabeth Rousseau-Harsany, Sainte-Justine UHC, Montreal, Quebec (board representative); Lindy Michelle Samson, Children's Hospital of Eastern Ontario, Ottawa, Ontario

Consultant: Dr Noni E MacDonald, IWK Health Centre, Halifax, Nova Scotia

Liaisons: Drs Upton Dilworth Allen, The Hospital for Sick Children, Toronto, Ontario (Canadian Pediatric AIDS Research Group); Scott Alan Halperin, IWK Health Centre, Halifax, Nova Scotia (Immunization Program, ACTIVE); Charles PS Hui, Children's Hospital of Eastern Ontario, Ottawa, Ontario (Health Canada, Committee to Advise on Tropical Medicine and Travel); Larry Pickering, American Academy of Pediatrics, Red Book Editor and ex-officio member of the Committee on Infectious Diseases, Elk Grove, Illinois, USA; Marina Ines Salvadori, Children's Hospital of Western Ontario, Ottawa, Ontario (Health Canada, National Advisory Committee on Immunization)

Principal authors: Drs Noni E MacDonald, IWK Health Centre, Halifax, Nova Scotia; Larry Pickering, American Academy of Pediatrics, Elk Grove, Illinois, USA

The recommendations in this statement do not indicate an exclusive course of treatment or procedure to be followed.

Variations, taking into account individual circumstances, may be appropriate. This article also appears in the May/June 2007 issue of *The Canadian Journal of Infectious Diseases & Medical Microbiology*.